Skip to main content

Table 1 JOSD1 Expression and Clinicopathological Features of HNSCC

From: JOSD1 promotes proliferation and chemoresistance of head and neck squamous cell carcinoma under the epigenetic regulation of BRD4

Clinicopathological Features JOSD1 expression Total P value
Low High
Gender
 Male 13 (38.2%) 21 (61.8%) 34 0.256
 Female 5 (62.5%) 3 (37.5%) 8
Age
 ≥ 60 9 (39.1%) 14 (60.9%) 23 0.591
 < 60 9 (47.4%) 10 (52.6%) 19
Smoke
 Yes 10 (40.0%) 15 (60.0%) 25 0.650
 No 8 (47.1%) 9 (52.9%) 17
Drink
 Yes 6 (30.0%) 14 (70.0%) 20 0.108
 No 12 (54.5%) 10 (45.5%) 22
T stage
 T1–T2 14 (58.3%) 10 (41.7%) 24 0.019*
 T3–T4 4 (22.2%) 14 (77.8%) 18
N stage
 N0 12 (52.2%) 11 (47.8%) 23 0.179
 N1–3 6 (31.6%) 13 (68.4%) 19
Clinical stage
 I–II 11 (57.9%) 7 (42.1%) 18 0.038*
 III–IV 7 (21.7%) 17 (78.3%) 24
Histological grade
 G1 5 (35.7%) 9 (64.3%) 14 0.532
 G2 11 (52.4%) 10 (47.6%) 21
 G3 2 (28.6%) 5 (71.4%) 7
Resistance
 PR 8 (72.7%) 3 (27.3%) 11 0.048*
 PD/SD 10 (32.3%) 21 (67.7%) 31
  1. The result was analyzed by the Pearson χ2 test. P values with signifirance were shown as asterisk
  2. * P < 0.05